Continuing Education (CE)
Bayer has sponsored a variety of continuing education (CE) programs, which were developed to improve awareness and understanding of stroke prevention conditions.
All accredited CE/CME programs listed below were created independently by third-party providers and follow the standards set forth in the ACCME Standards for Commercial Support/Integrity and Independence in Accredited Continuing Education, or other similar accrediting organizations. Responsibility and control over selection, content, faculty, educational materials, and venue for the educational programs belong solely to the providers and/or accreditors. Bayer does not provide any guidance regarding the content or faculty for any programs receiving funding.
The list below is limited to CE programs supported by Bayer.
Last updated August 2026.
Advancing Stroke Care: Understanding FXIa, Novel Therapies, and Patient-Centered Management
MED LEARNING GROUP
0.75 AMA PRA Category 1 Credits™
neurologists, primary care physicians, critical care physicians, hospitalists, advanced practice providers, nurse practitioners, and pharmacists, and other allied health professionals
Optimizing Secondary Stroke Prevention: Addressing Unmet Needs in Non-Cardioembolic Ischemic Stroke
PARTNERS FOR ADVANCING CLINICAL EDUCATION (JOINTLY PROVIDED WITH LETTERS & SCIENCE)
1.50 AMA PRA Category 1 Credit™
Clinical pharmacists, ambulatory care pharmacists, neurologists, primary care physicians, critical care physicians, cardiologists, neuro-cardiologists, hospitalists, advanced practice providers, nurses, and other clinicians involved in the management of stroke patients
Less Bleeding, More Prevention: A Nurse-Focused Review of the Paradigm-Shifting Promise of Factor XIa Inhibitors in Secondary Stroke Prevention
POSTGRADUATE INSTITUTE FOR MEDICINE AND POSTGRADUATE HEALTHCARE EDUCATION
2.0 contact hours (including 1.0 pharmacotherapy)
Registered nurses; advanced practice registered nurses
Safer Stroke Prevention on the Horizon? What the New Factor XIa Inhibitor Data Reveal
Medscape, LLC
0.50 AMA PRA Category 1 Credit™
International audience of neurologists, cardiologists, hematologists, primary care physicians, and nurses
Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention?
PeerVoice
1.50 AMA PRA Category 1 Credit™
Neurologists and clinicians involved in stroke prevention care
Secondary Stroke Prevention Today and Tomorrow: Where Evolving Antithrombotic Strategies May Fit Into Hospitalist Care
ANSWERS IN CME
0.50 AMA PRA Category 1 Credit™
Hospitalists/internists, APPs and other clinicians in the US
FXIa Remix! Keeping the Flow Without Missing a Beat
MEDCON International
0.50 AMA PRA Category 1 Credit™
Neurologists, hematologists, and healthcare professionals involved in managing patients with stroke
Advancing Secondary Stroke Prevention: How the Latest Evidence Informs Team-Based Practice
ANSWERS IN CME
0.50 AMA PRA Category 1 Credit™
Cardiovascular disease; critical care medicine; hospital medicine; internal medicine; interventional cardiology; neurocritical care clinicians
Preventing the Next Stroke: Factor XIa Inhibition From Evidence to Practice
Medscape, LLC
1.00 AMA PRA Category 1 Credit™
Neurologists, cardiologists, hematologists, primary care physicians, and nurses
Personalizing Antithrombotic Care: A Case-Based Look at Factor XIa Inhibition After Stroke
Medscape, LLC
1.00 AMA PRA Category 1 Credit™
Neurologists, cardiologists, hematologists, primary care physicians, and nurses
Turning Pathophysiologic Promise Into Evidence-Based Potential: Are Factor XIa Inhibitors Ready for Prime Time in Secondary Stroke Prevention?
PeerVoice
1.25 AMA PRA Category 1 Credit™
Family Practice; General Practice; Internal Medicine; Neurology; Nurse; Pharmacist; Physician Assistant; Other
A New Era in Stroke Prevention: Why OCEANIC Stroke Changes The Game
World Stroke Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
MEDCON International
Emerging Antithrombotic Therapies in Stroke Prevention: What’s New?
World Stroke Academy
Factor XIa Inhibitors: A New Paradigm in Secondary Stroke Prevention
World Stroke Academy
From Trial to Clinic: Applying OCEANIC-Stroke in Practice
World Stroke Academy
Incident stroke and time course of benefit of asundexian: analyses of the OCEANIC-STROKE trial
The Video Journal of Neurology
Inside OCEANIC-Stroke: Design, Results, and Key Insights
World Stroke Academy
Life after stroke: First steps in secondary stroke prevention
The Video Journal of Neurology
Navigating the Latest Evidence Surrounding Current and Emerging Strategies for Secondary Stroke Prevention
PeerVoice
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
ReachMD
OCEANIC-STROKE: Translating Landmark Results Into Clinical Practice
World Stroke Academy
Prespecified secondary analysis of OCEANIC-STROKE: asundexian in ischemic stroke subtypes
The Video Journal of Neurology
Primary results from OCEANIC-STROKE: asundexian for secondary stroke prevention
The Video Journal of Neurology
Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition
PeerVoice
What Comes Next After OCEANIC-Stroke for Stroke Prevention
World Stroke Academy
Follow Us
